Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
PART 1:
1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma.
PART 2:
To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.